Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072872
Filing Date
2025-05-15
Accepted
2025-05-15 17:26:36
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10285
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 250459
  Complete submission text file 0000950170-25-072872.txt   357147
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-85205 | Film No.: 25955978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G